Turkish Real Life Atrial Fibrillation in Clinical Practice: TRAFFIC Study

Basit Öğe Kaydı
dc.authorscopusid57203904952en_US
dc.authorscopusid35772955900en_US
dc.authorscopusid55676772500en_US
dc.authorscopusid56675897600en_US
dc.authorscopusid24773283300en_US
dc.authorscopusid26539005000en_US
dc.authorscopusid56824971000en_US
dc.contributor.authorKarabay, C.Y.
dc.contributor.authorTaşolar, H.
dc.contributor.authorKunak, A.Ü.
dc.contributor.authorÇap, M.
dc.contributor.authorAstarcıoğlu, M.A.
dc.contributor.authorŞen, T.
dc.contributor.authorKaplan, M.
dc.date.accessioned2024-08-23T16:07:32Z
dc.date.available2024-08-23T16:07:32Z
dc.date.issued2024en_US
dc.departmentDüzce Üniversitesien_US
dc.description.abstractBackground: Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia worldwide and is associated with an increased risk of thromboembolism, ischemic stroke, impaired quality of life, and mortality. The latest research that shows the prevalence and incidence of AF patients in Türkiye was the Turkish Adults’ Heart Disease and Risk Factors study, which included 3,450 patients and collected data until 2006/07.The Turkish Real Life Atrial Fibrillation in Clinical Practice (TRAFFIC) study is planned to present current prevalence data, reveal the reflection of new treatment and risk approaches in our country, and develop new prediction models in terms of outcomes. Methods: The TRAFFIC study is a national, prospective, multicenter, observational registry. The study aims to collect data from at least 1900 patients diagnosed with atrial fibrillation, with the participation of 40 centers from Türkiye. The following data will be collected from patients: baseline demographic characteristics, medical history, vital signs, symptoms of AF, ECG and echocardiographic findings, CHADS2-VASC2 and HAS-BLED (1-year risk of major bleeding) risk scores, interventional treatments, antithrombotic and antiarrhythmic medications, or other medications used by the patients. For patients who use warfarin, international normalized ratio levels will be monitored. Follow-up data will be collected at 6, 12, 18, and 24 months. Primary endpoints are defined as systemic embolism or major safety endpoints (major bleeding, clinically relevant nonmajor bleeding, and minor bleeding as defined by the International Society on Thrombosis and Hemostasis). The main secondary endpoints include major adverse cardiovascular events (systemic embolism, myocardial infarction, and cardiovascular death), all-cause mortality, and hospitalizations due to all causes or specific reasons. Results: The results of the 12-month follow-up of the study are planned to be shared by the end of 2023. Conclusion: The TRAFFIC study will reveal the prevalence and incidence, demographic characteristics, and risk profiles of AF patients in Türkiye. Additionally, it will provide insights into how current treatments are reflected in this population. Furthermore, risk prediction modeling and risk scoring can be conducted for patients with AF. © 2024 Turkish Society of Cardiology. All rights reserved.en_US
dc.description.sponsorshipAhmet Yılmaz MD; Gökhan Gözübüyük MDen_US
dc.identifier.doi10.14744/AnatolJCardiol.2023.3616
dc.identifier.endpage93en_US
dc.identifier.issn2149-2263
dc.identifier.issue2en_US
dc.identifier.pmid38168008en_US
dc.identifier.scopus2-s2.0-85184755603en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage87en_US
dc.identifier.urihttps://doi.org/10.14744/AnatolJCardiol.2023.3616
dc.identifier.urihttps://hdl.handle.net/20.500.12684/14710
dc.identifier.volume28en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTurkish Society of Cardiologyen_US
dc.relation.ispartofAnatolian Journal of Cardiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectArrhythmiasen_US
dc.subjectatrial fibrillationen_US
dc.subjectatrial fibrillation/flutteren_US
dc.subjectbleedingen_US
dc.subjectcatheter ablationen_US
dc.subjectantiarrhythmic agenten_US
dc.subjectanticoagulant agenten_US
dc.subjecthemoglobin A1cen_US
dc.subjecthigh density lipoprotein cholesterolen_US
dc.subjectlow density lipoprotein cholesterolen_US
dc.subjectwarfarinen_US
dc.subjectadulten_US
dc.subjectArticleen_US
dc.subjectatrial fibrillationen_US
dc.subjectatrioventricular conductionen_US
dc.subjectbleedingen_US
dc.subjectbleeding risk scoreen_US
dc.subjectbrain hemorrhageen_US
dc.subjectcardiovascular diseaseen_US
dc.subjectcerebrovascular accidenten_US
dc.subjectCHA2DS2-VASc scoreen_US
dc.subjectCHADS2 scoreen_US
dc.subjectchronic kidney failureen_US
dc.subjectclinical practiceen_US
dc.subjectdiabetes mellitusen_US
dc.subjectdiastolic blood pressureen_US
dc.subjectdyslipidemiaen_US
dc.subjectechocardiographyen_US
dc.subjectelectrocardiogramen_US
dc.subjectestimated glomerular filtration rateen_US
dc.subjectfasting blood glucose levelen_US
dc.subjectfollow upen_US
dc.subjectglucose blood levelen_US
dc.subjecthealth care costen_US
dc.subjectheart arrhythmiaen_US
dc.subjectheart atrium flutteren_US
dc.subjectheart deathen_US
dc.subjectheart diseaseen_US
dc.subjectheart failureen_US
dc.subjectheart infarctionen_US
dc.subjecthumanen_US
dc.subjecthypercholesterolemiaen_US
dc.subjecthypertensionen_US
dc.subjecthypothyroidismen_US
dc.subjectinternational normalized ratioen_US
dc.subjectischemic strokeen_US
dc.subjectkidney failureen_US
dc.subjectmortalityen_US
dc.subjectquality of lifeen_US
dc.subjectrisk factoren_US
dc.subjectsmokingen_US
dc.subjectthromboembolismen_US
dc.titleTurkish Real Life Atrial Fibrillation in Clinical Practice: TRAFFIC Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu